References and notes
7. Synthesis of racemic lasofoxifene via heterogeneous
hydrogenation of nafoxidine 3:
(
a)
agonists/antagonists. PCT Int. Appl. WO/96/21656 A1;
b) Rosati RL, Jardine Da Silva P, Cameron KO, Thompson DD,
Cameron
KO,
Jardine
DaSilva
PA.
Estrogen
1
.
(a) Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J,
Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JÅ.
Physiol Rev. 2001;81:1535–1565;
(
Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold
AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole
MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie
CM, Qi H, Simmons HA, Tkalcevic GT. J Med Chem. 1998;41:
(
(
b) Shang Y, Brown M. Science 2002;295:2465–2468;
c) Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N.
Mol Cell Endocrinol. 2005;239:27–36;
(
(
d) Deroo BJ, Korach KS. J Clin Invest. 2006;116:561–567;
e) Heldring N, Pike A, Andersson S, Matthews J, Cheng G,
2
(
5
928–2931;
c) Lehner RS, Taber GP. Process for preparation of cis-6-phenyl-
-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-
tetrahydronaphthalene hydrochloride via stereoselective
Hartman J, Tujague M, Ström A, Treuter E, Warner M,
Gustafsson JÅ. Physiol Rev. 2007;87:905–931;
(
1
(
2
f) Musa MA, Khan MO, Cooperwood JS. Curr Med Chem. 2007;
4:1249–1261;
g) Baumann CK, Castiglione-Gertsch M. Drugs 2007;67:2335–
353;
h) Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB.
Obstet Gynecol Surv. 2008;63:163–181;
hydrogenation of nafoxidine hydrochloride. PCT Int. Appl.
WO/2006/136944 A1;
(
2
(
d) Sano Y, Nakata K, Otoyama T, Umeda S, Shiina I. Chem Lett.
007;36:40–41;
e) Czarnik AW. Deuterium-enriched lasofoxifene. U.S. Pat. Appl.
US/2009/0062374 A1;
(
(
(
i) Pickar JH, MacNeil T, Ohleth K. Maturitas 2010;67:129–138;
j) Maximov PY, Lee TM, Jordan VC. Curr Clin Pharmacol.
(
(
f) Nakata K, Sano Y, Shiina I. Molecules 2010;15:6773–6794;
g) Khan MA, Trivedi NR, Kandasamy NN, Patil DG, Pandey
2
013;8:135–155.
For use of SERMs in treatment of osteoporosis, see:
a) Cho CH, Nuttall ME. Expert Opin Emerging Drugs 2001;6:
37–154;
b) Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Drugs
Aging 2007;24:361–379;
c) Lewiecki EM. Expert Opin Emerging Drugs 2009;14:129–144.
VK, Sinha S. Process for the preparation of lasofoxifene tartrate.
PCT Int. Appl. WO/2010/125578 A1.
2
3
.
.
(
1
(
8
.
Heterogeneous
dihydronaphthalene derivatives:
a) Tatee T, Carlson KE, Katzenellenbogen JA, Robertson DW,
Katzenellenbogen BS. J Med Chem. 1979;22:1509–1517;
b) Chiu CKf. Process for cis-1-2-[4-(6-methoxy-2-phenyl-
,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine. Jpn.
Kokai Tokkyo Koho JP/2000/327670 A;
c) Blizzard TA, Morgan II JD, Chan W, Birzin ET, Pai LY,
hydrogenation
of
3,4-diphenyl-1,2-
(
(
(
1
For application of SERMs in prevention and treatment of breast
cancer, see:
(
a) Peng J, Sengupta S, Jordan VC. Anti-Cancer Agents Med
Chem. 2009;9:481–499;
b) Wang T, You Q, Huang FS, Xiang H. Mini-Rev Med Chem.
009;9:1191–1201;
(
Hayes EC, DaSilva CA, Mosley RT, Yang YT, Rohrer SP,
DiNinno F, Hammond ML. Bioorg Med Chem Lett. 2005;15:
(
2
5
124–5128.
Chiu CK, Meltz M. Preparation of (-)-cis-(5R,6S)-6-phenyl-5-[4-
2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-
(
(
(
c) Obiorah I, Jordan VC. Maturitas 2011;70:315–321;
d) Vogel VG. Curr Drug Targets 2011;12:1874–1887;
e) Cuzick, J.; DeCensi, A.; Arun, B.; Brown, P. H.; Castiglione,
9
.
(
ol D-tartrate by optical resolution. PCT Int. Appl. WO/97/16434
A1.
M.; Dunn, B.; Forbes, J. F.; Glaus, A.; Howell, A.; von
Minckwitz, G.; Vogel, V.; Zwierzina, H. Lancet Oncol. 2011;12:
1
1
1
1
1
1
0. Yang X, Reinhold AR, Rosati RL, Liu KK. Org Lett. 2000;2:
025–4027.
4
96–503.
For the applications of lasofoxifene in therapy, see:
a) Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Curr Top Med
Chem. 2006;6:181–202;
b) McClung MR, Siris E, Cummings S, Bolognese M, Ettinger
M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. Menopause
006;13:377–386;
c) Gennari L, Merlotti D, De Paola V, Nuti R. Core Evid. 2009;
:113–129;
4
4
.
1. Yoshida H, Yoshida R, Mukae M, Ohshita J, Takaki K. Chem
Lett. 2011;40:1272–1274.
2. Zanotti-Gerosa A, Gazić Smilović I, Časar Z. Org Chem Front.
(
(
2
017;4:2311–2322.
3. Camerman N, Chan LYY, Camerman A. J Med Chem. 1980;23:
41–945.
4. Bindal RD, Durani S, Kapil RS, Anand N. Synthesis 1982;405–
07.
5. Lu Y, Huang Y, Chen Z, Lin Y, Zhao X. Res Chem Intermed.
015;41:6051–6056.
2
(
4
9
4
(
(
(
d) Lewiecki EM. Ther Clin Risk Manag. 2009;5:817–827;
e) Gennari L. Expert Opin Pharmacother. 2009;10:2209–2220;
f) Gennari L, Merlotti D, Nuti R. Clin Interv Aging 2010;5:19–
2
1
1
6. Umareddy P, Reddy Arava V. Synth Commun. 2016;46:309–313.
7. Walkinshaw AJ, Xu W, Suero MG, Gaunt MJ. J Am Chem Soc.
2
(
9
(
9;
g) Swan VJD, Hamilton CJ, Jamal SA. Adv Ther. 2010;27:917–
32;
h) Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic
2
013;135:12532–12535.
1
1
8. This work presented in this manuscript is based on our patent
application: Gazić Smilović I, Seechurn C, Colacot TJ. Process for
the preparation of α-substituted ketones and their application in
synthesis of pharmaceutically active compounds. PCT Int. Appl.
WO/2012159981 A2..
S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J,
Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D,
Neven P, Eastell R. N Engl J Med. 2010;362:686–696;
(
i) Lacroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR,
9. For selected articles and reviews on α-arylation of ketones, see:
Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell
R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M,
Vukicevic S. J Natl Cancer Inst. 2010;102:1706–1715;
(
a) Palucki M, Buchwald SL. J Am Chem Soc. 1997;119:11108–
1109;
b) Hamann BC, Hartwig JF. J Am Chem Soc. 1997;119:12382–
2383;
c) Johansson CCC, Colacot TJ. Angew Chem Int Ed. 2010;49:
76–707;
d) Johansson Seechurn CCC, Kitching MO, Colacot TJ, Snieckus
V. Angew Chem Int Ed. 2012;51:5062–5085;
e) Marelli E, Corpet M, Davies SR, Nolan SP. Chem Eur J.
014;20:17272–17276;
f) Sivanandan ST, Shaji A, Ibnusaud I, Johansson Seechurn CCC,
Colacot TJ. Eur J Org Chem. 2015;38–49;
g) Yin HY, Lin XL, Li SW, Shao LX. Org Biomol Chem.
015;13:9012–9021.
0. (a) Grasa GA, Colacot TJ. Org Lett. 2007;9:5489–5492;
b) Grasa GA, Colacot TJ. Org Proc Res Dev. 2008;12:522–529.
1
(
1
(
6
(
(
j) Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R,
Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R,
Welty F, Cummings S. Circulation 2010;122:1716–1724;
(
k) Gennari, L.; Merlotti, D.; Stolakis, K.; Nuti, R. Expert Opin
Drug Discovery 2011;6:205–217;
l) Peterson GM, Naunton M, Tichelaar LK, Gennari L. Ann
Pharmacother. 2011;45:499–509;
m) Andersson A, Bernardi AI, Stubelius A, Nurkkala-Karlsson
(
(
2
(
(
M, Ohlsson C. Rheumatology 2016;55:553–563.
(a) Goldstein SR, Portman D, Symons J. Menopause
5
6
.
.
(
2
2
(
1
(
1
(
015;22:1372–1372;
b) Kagan R, Symons J, Portman D. Menopause 2015;22:1374–
374;
c) Portman DJ, Simon JA, Symons J. Menopause 2015;22:1374–
375;
d) Portman DJ, Symons J. Menopause 2015;22:1385–1386.
2
2
(
1. 2-Aryl-1-tetralones are prone to rapid oxidation in solution under
basic, neutral and acidic conditions to the corresponding 2-aryl-2-
hydroxytetralones, see: Ishikawa T, Hino K, Yoneda T, Murota M,
Yamaguchi K, Watanabe T. J Org Chem. 1999;64:5691–5695.
Gennari L, Merlotti D, Martini G, Nuti R. Expert Opin Investig
Drugs 2006;15:1091–1103.